Sugi Predict

Sugi Predict / Compounds / SCHEMBL711607

SCHEMBL711607

SCHEMBL711607

NC(=O)CC[C@H](N)C(=O)OC(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.60
▸ BLM P54132 1/20 0.60
▸ PMP22 Q01453 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ DPP4 P27487 1/20 0.43
▸ DPP8 Q6V1X1 1/20 0.43
▸ DPP9 Q86TI2 1/20 0.43
▸ GRM8 O00222 1/20 0.39
▸ GRM6 O15303 1/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GSR P00390 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ GRIK1 P39086 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ GRIA1 P42261 1/20 0.39
▸ GRIA2 P42262 1/20 0.39
▸ GRIA3 P42263 1/20 0.39
▸ SLC1A3 P43003 1/20 0.39
▸ SLC1A2 P43004 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28571398 0.92 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL352342 0.92 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL204796 0.92 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL3411544 0.92 BLM (0.57) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL3178198 0.92 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL29240009 0.92 BLM (0.57) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL726834 0.92 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL7176759 0.91 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL285917 0.90 ALOX15 (0.50) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL432399 0.90 PMP22 (0.50) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112964682-B Method for visually and quantitatively marking aggregated functional protein in cells 中国科学院高能物理研究所 2022-02-25 — — CN claimed
CN-112964682-A Method for visually and quantitatively marking aggregated functional protein in cells 中国科学院高能物理研究所 2021-06-15 — — CN claimed
CN-110522744-A The material and method of pulmonary lesions for improving lung function and for preventing and/or treating radiation-actuate UNIV FLORIDA 2019-12-03 — — CN claimed
US-9849144-B2 Glutamine and trehalose compositions Healios Oncology Nutrition, LLC (US) 2017-12-26 — — US claimed
CN-102229645-B Method for preparing immune seven peptides CHENG YUN 2013-08-14 — — CN claimed
CN-102229645-A Method for preparing immune seven peptides YUN CHENG 2011-11-02 — — CN claimed
CN-101781325-A Gallium salicylaldehyde amino acid Schiff base quaternary coordination compound, preparation method and application thereof UNIV BEIJING NORMAL 2010-07-21 — — CN claimed
EP-0052296-B1 GLUTAMINE DERIVATIVES USABLE FOR CURING IMMUNE DISEASES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING SAID DERIVATIVES MITSUBISHI KASEI CORPORATION (JP) 1984-06-27 — — EP claimed
CN-119859263-A Polyimide-based precursor and composition containing same 德山新勒克斯有限公司 2025-04-22 — — CN disclosed
US-11969494-B2 Non-therapeutic oral use of a composition for whitening and/or lightening the skin comprising cystine and glutathione in a cystine-glutathione ratio ranging from 1.5 to 4 BRETAGNE CHIMIE FINE (FR) 2024-04-30 — — US disclosed
CN-115315477-A Thermoplastic starch composition, method for producing same, and use thereof 大象（株） 2022-11-08 — — CN disclosed
CN-112964682-B Method for visually and quantitatively marking aggregated functional protein in cells 中国科学院高能物理研究所 2022-02-25 — — CN disclosed
US-20220016005-A1 NON-THERAPEUTIC ORAL USE OF A COMPOSITION FOR WHITENING AND/OR LIGHTENING THE SKIN COMPRISING CYSTINE AND GLUTATHIONE IN A CYSTINE-GLUTATHIONE RATIO RANGING FROM 1.5 TO 4 BRETAGNE CHIMIE FINE (FR) 2022-01-20 — — US disclosed
US-20210292289-A1 HETEROCYCLIC GLUTAMINASE INHIBITORS CALITHERA BIOSCIENCES, INC. 2021-09-23 — — US disclosed
US-5668253-A POLYPEPTIDES AS ANTIGENS AND ANTIBODIES HEALTH RESEARCH, INC. (US) 1997-09-16 — — US disclosed
WO-1993021304-A1 METHOD FOR THE INHIBITION OF THE PROLIFERATION OF CANCER CELLS IN A TUMOR THE OHIO STATE UNIVERSITY (US) 1993-10-28 — — WO disclosed
US-5206220-A Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-04-27 — — US disclosed
US-4892733-A DRUG DELIVERY, HOMO-AND CO-POLYMERS OF ASPARTIC AND GLUTAMIC ACID IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-01-09 — — US disclosed
EP-0250492-A1 BIODEGRADABLE SYNTHETIC POLYPEPTIDE AND ITS UTILIZATION IN THERAPEUTICS BATTELLE MEMORIAL INSTITUTE (CH) 1988-01-07 — — EP disclosed
WO-1987003891-A1 BIODEGRADABLE SYNTHETIC POLYPEPTIDE AND ITS UTILIZATION IN THERAPEUTICS BATTELLE MEMORIAL INSTITUTE (CH) 1987-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292289-A1 HETEROCYCLIC GLUTAMINASE INHIBITORS GLS, GLS2, GLUL ALOX15 2158/4885BLM 3461/4885PMP22 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.